Bresnihan Barry
Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland.
Arthritis Res Ther. 2003;5(6):271-8. doi: 10.1186/ar1003. Epub 2003 Oct 2.
Synovial tissue is readily accessible by closed needle or arthroscopic biopsy. These techniques provide adequate tissue for most diagnostic requirements. Examination of synovial tissue can assist in the diagnosis of some joint infections, and in several atypical or rare synovial disorders. Histological confirmation is not normally required for diagnosis of the common forms of inflammatory arthritis, including rheumatoid arthritis (RA). In patients with either established or early RA, immunohistological measures of inflammation in synovial tissue are associated with clinical measures of disease activity, may predict the clinical outcome, and change in response to treatment. Surrogate markers of disease activity and outcome that have been identified in synovial tissue include components of the cellular infiltrate, and several mediators of inflammation and matrix degradation. There is evidence that the very early introduction of disease-modifying therapy inhibits progressive structural damage maximally. Clinicians exploiting this 'window of opportunity' therefore require very early indicators of the diagnosis and outcome in patients who present with an undifferentiated inflammatory arthritis. Some immunohistological features have been described that distinguish patients who are likely to develop progressive RA and who might benefit most from early aggressive therapeutic intervention. In this regard, the inclusion of pharmacogenomic and proteomic techniques in the analysis of synovial tissue presents some exciting possibilities for future research.
滑膜组织可通过闭合针穿刺活检或关节镜活检轻松获取。这些技术可为大多数诊断需求提供足够的组织。滑膜组织检查有助于诊断某些关节感染以及一些非典型或罕见的滑膜疾病。对于包括类风湿关节炎(RA)在内的常见炎症性关节炎形式,通常不需要组织学确诊。在已确诊或早期RA患者中,滑膜组织炎症的免疫组织学指标与疾病活动的临床指标相关,可能预测临床结局,并随治疗反应而变化。在滑膜组织中已确定的疾病活动和结局替代标志物包括细胞浸润成分以及几种炎症和基质降解介质。有证据表明,尽早引入改善病情的治疗可最大程度地抑制进行性结构损伤。因此,利用这一“机会窗口”的临床医生需要在出现未分化炎症性关节炎的患者中获得非常早期的诊断和结局指标。已经描述了一些免疫组织学特征,这些特征可区分可能发展为进行性RA的患者以及可能从早期积极治疗干预中获益最大的患者。在这方面,将药物基因组学和蛋白质组学技术纳入滑膜组织分析为未来研究提供了一些令人兴奋的可能性。